Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent malignant pancreatic tumor. Few studies have shown how often PDACs arise from cystic precursor lesions. This special report aims to summarize the evidence on the progression of precancerous lesions to PDAC. A review of the literature found four studies that discussed pancreatic intraepithelial lesions (PanINs), three that discussed mucinous cystic neoplasms (MCN) and five that discussed intraductal papillary neoplasms (IPMNs). PanINs were the most common precursors lesion, with approximately 80% of PDACs originating from this lesion. The lack of evidence characterizing the features of PDAC precursor cystic lesions potentially leads to a subset of patients undergoing surgery unnecessarily. Advancements in molecular techniques could allow the study of cystic lesions at a genetic level, leading to more personalized management.

Cite

CITATION STYLE

APA

Chidambaram, S., Kawka, M., Gall, T. M. H., Cunningham, D., & Jiao, L. R. (2022). Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma? Future Oncology, 18(23), 2605–2612. https://doi.org/10.2217/fon-2021-1545

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free